Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients

F. Baldanti, S. Paolucci, R. Maserati, F. Maggiolo, A. Pan, F. Castelli, R. Gulminetti, G. Comolli, A. Chiesa, G. Gerna

Research output: Contribution to journalArticle

Abstract

The efficacy of two-class versus three-class antiretroviral salvage treatment was analyzed retrospectively in 63 HIV-infected patients in whom highly active antiretroviral therapy failed. Twenty-eight patients (group A) received two-class therapy, and 35 patients (group B) received three-class therapy. After 3 months of treatment, a significantly greater proportion of patients in group B (23/35, 65.7%) than in group A (8/28, 28.5%) showed a ≥ 1 log10 decrease in the plasma HIV RNA level (P = 0.0034). However, after 9-12 months, 12 of 23 (52.1%) group B responders showed viral load rebound. The results were partially explained by the finding that, at baseline, the great majority (21/27, 77.7%) of group A patients showed mutations conferring resistance to all drugs administered, whereas in group B patients' susceptibility to at least two drug classes was retained. However, after 9-12 months of therapy, most (18/20, 90%) of the shortterm responders in group B showed emergence of additional mutations that hampered long-term response.

Original languageEnglish
Pages (from-to)380-384
Number of pages5
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume19
Issue number5
Publication statusPublished - 2000

Fingerprint

Salvage Therapy
Highly Active Antiretroviral Therapy
HIV
Mutation
Therapeutics
Viral Load
Pharmaceutical Preparations
RNA

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

@article{e6cac1a408144d2494640885e4cabcae,
title = "Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients",
abstract = "The efficacy of two-class versus three-class antiretroviral salvage treatment was analyzed retrospectively in 63 HIV-infected patients in whom highly active antiretroviral therapy failed. Twenty-eight patients (group A) received two-class therapy, and 35 patients (group B) received three-class therapy. After 3 months of treatment, a significantly greater proportion of patients in group B (23/35, 65.7{\%}) than in group A (8/28, 28.5{\%}) showed a ≥ 1 log10 decrease in the plasma HIV RNA level (P = 0.0034). However, after 9-12 months, 12 of 23 (52.1{\%}) group B responders showed viral load rebound. The results were partially explained by the finding that, at baseline, the great majority (21/27, 77.7{\%}) of group A patients showed mutations conferring resistance to all drugs administered, whereas in group B patients' susceptibility to at least two drug classes was retained. However, after 9-12 months of therapy, most (18/20, 90{\%}) of the shortterm responders in group B showed emergence of additional mutations that hampered long-term response.",
author = "F. Baldanti and S. Paolucci and R. Maserati and F. Maggiolo and A. Pan and F. Castelli and R. Gulminetti and G. Comolli and A. Chiesa and G. Gerna",
year = "2000",
language = "English",
volume = "19",
pages = "380--384",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "5",

}

TY - JOUR

T1 - Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients

AU - Baldanti, F.

AU - Paolucci, S.

AU - Maserati, R.

AU - Maggiolo, F.

AU - Pan, A.

AU - Castelli, F.

AU - Gulminetti, R.

AU - Comolli, G.

AU - Chiesa, A.

AU - Gerna, G.

PY - 2000

Y1 - 2000

N2 - The efficacy of two-class versus three-class antiretroviral salvage treatment was analyzed retrospectively in 63 HIV-infected patients in whom highly active antiretroviral therapy failed. Twenty-eight patients (group A) received two-class therapy, and 35 patients (group B) received three-class therapy. After 3 months of treatment, a significantly greater proportion of patients in group B (23/35, 65.7%) than in group A (8/28, 28.5%) showed a ≥ 1 log10 decrease in the plasma HIV RNA level (P = 0.0034). However, after 9-12 months, 12 of 23 (52.1%) group B responders showed viral load rebound. The results were partially explained by the finding that, at baseline, the great majority (21/27, 77.7%) of group A patients showed mutations conferring resistance to all drugs administered, whereas in group B patients' susceptibility to at least two drug classes was retained. However, after 9-12 months of therapy, most (18/20, 90%) of the shortterm responders in group B showed emergence of additional mutations that hampered long-term response.

AB - The efficacy of two-class versus three-class antiretroviral salvage treatment was analyzed retrospectively in 63 HIV-infected patients in whom highly active antiretroviral therapy failed. Twenty-eight patients (group A) received two-class therapy, and 35 patients (group B) received three-class therapy. After 3 months of treatment, a significantly greater proportion of patients in group B (23/35, 65.7%) than in group A (8/28, 28.5%) showed a ≥ 1 log10 decrease in the plasma HIV RNA level (P = 0.0034). However, after 9-12 months, 12 of 23 (52.1%) group B responders showed viral load rebound. The results were partially explained by the finding that, at baseline, the great majority (21/27, 77.7%) of group A patients showed mutations conferring resistance to all drugs administered, whereas in group B patients' susceptibility to at least two drug classes was retained. However, after 9-12 months of therapy, most (18/20, 90%) of the shortterm responders in group B showed emergence of additional mutations that hampered long-term response.

UR - http://www.scopus.com/inward/record.url?scp=0034087765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034087765&partnerID=8YFLogxK

M3 - Article

C2 - 10898142

AN - SCOPUS:0034087765

VL - 19

SP - 380

EP - 384

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 5

ER -